Car T-Cell Therapy

Although chimeric antigen receptor T-cell therapy has delivered previously unthinkable remission outcomes to patients with lupus and other rheumatic diseases, the cells currently in use remain “old fashioned,” according to a speaker.

Although chimeric antigen receptor T-cell therapy has raised hopes for long-term remission in autoimmune disease, it has several limitations that may be overcome instead through bispecific T-cell-engaging antibodies, according to a speaker.

A new retrospective analysis has added to building evidence that suggests chimeric antigen receptor T-cell therapy does not directly cause secondary malignancies.

Chimeric antigen receptor T-cell therapy improves not only lupus disease activity but also other related conditions that impact quality of life, according to a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.

A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the long-term, drug-free remission from autoimmune diseases observed after treatment, according to a speaker.

In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of oncology at Mayo Clinic, discusses recent advancements in the treatment and study of mantle cell lymphoma.